NeuBase Therapeutics (NBSE) Short Interest Ratio & Short Volume → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Free NBSE Stock Alerts $0.43 +0.01 (+1.88%) (As of 09:39 AM ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability NeuBase Therapeutics Short Interest DataCurrent Short Volume149,100 sharesPrevious Short Volume80,500 sharesChange Vs. Previous Month+85.22%Dollar Volume Sold Short$67,080.09Short Interest Ratio / Days to Cover0.6Last Record DateMarch 31, 2024Outstanding Shares3,750,000 sharesFloat Size3,030,000 sharesShort Percent of Float4.92%Today's Trading Volume12,466 sharesAverage Trading Volume206,487 sharesToday's Volume Vs. Average6% Short Selling NeuBase Therapeutics ? Sign up to receive the latest short interest report for NeuBase Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNBSE Short Interest Over TimeNBSE Days to Cover Over TimeNBSE Percentage of Float Shorted Over Time Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… NeuBase Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2024149,100 shares $67,080.09 +85.2%4.9%0.6 $0.45 3/15/202480,500 shares $78,004.50 -59.7%2.7%0.4 $0.97 2/29/2024199,800 shares $171,828.00 +2,003.2%6.6%1 $0.86 2/15/20249,500 shares $6,508.45 -24.6%0.3%0 $0.69 1/31/202412,600 shares $8,983.80 +14.6%0.4%0 $0.71 1/15/202411,000 shares $7,291.90 -82.6%0.4%0 $0.66 Get the Latest News and Ratings for NBSE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202363,300 shares $46,848.33 +245.9%2.1%0.2 $0.74 12/15/202318,300 shares $12,810.00 +105.6%0.6%0.1 $0.70 11/30/20238,900 shares $8,778.96 -27.6%0.3%0 $0.99 11/15/202312,300 shares $8,007.30 +38.2%0.5%0 $0.65 10/31/20238,900 shares $5,651.50 -53.9%0.6%0 $0.64 10/15/202319,300 shares $14,457.63 -15.4%1.2%0 $0.75 9/30/202322,800 shares $19,831.44 -89.9%1.4%0 $0.87 9/15/2023225,600 shares $293,280.00 +30.8%14.0%0.1 $1.30 8/31/2023172,500 shares $167,325.00 +130.3%19.3%0.1 $0.97 8/15/202374,900 shares $51,531.20 +82.2%3.8%0.4 $0.69 7/31/202341,100 shares $57,129.00 -61.4%2.4%0.3 $1.39 7/15/2023106,600 shares $187,616.00 +49.1%7.5%1.4 $1.76 6/30/202371,500 shares $132,275.00 +108.5%5.0%1 $1.85 6/15/202334,300 shares $1.89 million -93.8%2.4%0.5 $55.20 5/31/2023554,800 shares $98,809.88 -1.7%2.0%1.2 $0.18 5/15/2023564,400 shares $108,929.20 +0.7%2.0%1.3 $0.19 4/30/2023560,400 shares $75,654.00 +64.4%2.0%1.1 $0.14 4/15/2023340,900 shares $57,271.20 +35.5%1.2%0.7 $0.17 3/31/2023251,600 shares $46,546.00 -8.1%0.9%0.8 $0.19 3/15/2023273,800 shares $51,282.74 -15.1%1.0%0.8 $0.19 2/28/2023322,500 shares $74,175.00 -46.3%1.2%0.9 $0.23 2/15/2023600,100 shares $169,708.28 +127.1%2.2%1.8 $0.28 1/31/2023264,300 shares $60,181.11 -13.2%0.9%1 $0.23 1/15/2023304,400 shares $78,961.36 -24.7%1.0%1.2 $0.26 12/30/2022404,400 shares $76,916.88 +27.1%1.4%1.8 $0.19 12/15/2022318,200 shares $63,130.88 +12.0%1.1%1.7 $0.20 11/30/2022284,200 shares $68,122.74 -5.1%1.0%1.8 $0.24 11/15/2022299,500 shares $86,855.00 -24.1%1.0%1.9 $0.29 10/31/2022394,500 shares $113,221.50 +11.8%1.4%3.2 $0.29 10/15/2022353,000 shares $95,592.40 +10.4%1.2%3.4 $0.27 9/30/2022319,900 shares $126,360.50 -3.6%1.1%4.3 $0.40 9/15/2022331,700 shares $181,771.60 -3.8%1.1%5.1 $0.55 8/31/2022344,800 shares $208,810.88 -7.0%1.2%5.5 $0.61 8/15/2022370,900 shares $422,826.00 -2.2%1.3%6.4 $1.14I have a unique way to “hijack” the stock market. (Ad)I have a unique way to “hijack” the stock market. And it’s not a matter of picking the next, big Amazon-like stock… Or guessing on the next A.I. moonshot like NVDA… This is not as hard as making amazing predictions like those.You can see more details of my unique “hijack” method if you click here now. NBSE Short Interest - Frequently Asked Questions What is NeuBase Therapeutics' current short interest? Short interest is the volume of NeuBase Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 149,100 shares of NBSE short. 4.92% of NeuBase Therapeutics' shares are currently sold short. Learn More on NeuBase Therapeutics' current short interest. What is a good short interest ratio for NeuBase Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NBSE shares currently have a short interest ratio of 1.0. Learn More on NeuBase Therapeutics's short interest ratio. What is a good short interest percentage for NeuBase Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.92% of NeuBase Therapeutics' floating shares are currently sold short. Is NeuBase Therapeutics' short interest increasing or decreasing? NeuBase Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 149,100 shares, an increase of 85.2% from the previous total of 80,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuBase Therapeutics' float size? NeuBase Therapeutics currently has issued a total of 3,750,000 shares. Some of NeuBase Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuBase Therapeutics currently has a public float of 3,030,000 shares. How does NeuBase Therapeutics' short interest compare to its competitors? 4.92% of NeuBase Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to NeuBase Therapeutics: PainReform Ltd. (1.21%), GRI Bio, Inc. (1.81%), Galmed Pharmaceuticals Ltd. (1.10%), 180 Life Sciences Corp. (8.36%), Panbela Therapeutics, Inc. (2.36%), Dermata Therapeutics, Inc. (1.73%), Comera Life Sciences Holdings, Inc. (2.38%), InMed Pharmaceuticals Inc. (0.17%), Qualigen Therapeutics, Inc. (1.74%), Baudax Bio, Inc. (1.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short NeuBase Therapeutics stock? Short selling NBSE is an investing strategy that aims to generate trading profit from NeuBase Therapeutics as its price is falling. NBSE shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuBase Therapeutics? A short squeeze for NeuBase Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NBSE, which in turn drives the price of the stock up even further. How often is NeuBase Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NBSE, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: PRFX Short Interest GRI Short Interest GLMD Short Interest ATNF Short Interest PBLA Short Interest DRMA Short Interest CMRA Short Interest INM Short Interest QLGN Short Interest BXRX Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NBSE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media